2015 American Transplant Congress » Poster Session A: Kidney Immunosuppression: Induction Therapy

Date: Saturday, May 2, 2015

Time: 5:30pm-7:30pm

Location: Exhibit Hall E

Session Type: Poster Session

Meeting: 2015 American Transplant Congress

5:30pm-7:30pm: A Comparison of Alemtuzumab and Antithymocyte Globulin Induction in High-Risk, Non-Sensitized African American Renal Transplant Recipients

M. Janusek,¹ S. Patel,² K. Galen,¹ P. West-Thilke,¹ E. Benedetti,¹ J. Thielke.¹

5:30pm-7:30pm: A Novel Maintenance Regimen With Calcineurin Inhibitor, MMF and Everolimus Initiated By Dual Induction Therapy With Anti-CD20/25 Antibodies in Renal Transplantation

N. Masaki, K. Iwado, I. Nakagima, S. Fuchinoue.

5:30pm-7:30pm: Alemtuzumab Dose Adjusted for Weight Reduces Infection Post-Renal Transplantation

C.-H. Yoon, M. Willicombe, C. Jogia, R. Charif, J. Galliford, A. McLean, D. Taube.

5:30pm-7:30pm: Alemtuzumab in Elderly Renal Transplant Recipients Is Not Associated With a Poor Outcome

D.-A. Moutzouris, L. Koizia, M. Willicombe, R. Corbett, N. Duncan, J. Galliford, A. McLean, D. Taube.

5:30pm-7:30pm: Delayed Graft Function in Patients Receiving Alemtuzumab Induction Therapy

M. Shindorf,¹ D. Fumo,¹ M. Weis,¹ W. Qu,¹ M. Rees,^1,2 J. Ortiz.¹

5:30pm-7:30pm: Early Use of Anti-Lymphocyte Antibody in Kidney Transplant Recipients With Delayed Graft Function Can Produce Desirable Post-Transplant Results

J. Lee, J. Lee, D. Joo, K. Huh, S. Kim, Y. Kim, M. Kim.

5:30pm-7:30pm: Effect of Induction in Renal Transplant Recipients Aged 70 and Over

M. Lubetzky, M. Ajaimy, L. Kamal, G. DeBoccardo, E. Akalin.

5:30pm-7:30pm: Efficacy and Safety of Induction Therapy With Monoclonal Versus Polyclonal Antibodies in Kidney Transplant Recipients in the Last Five Years (2008-2013) in Our Institution

M. Fernández, M. López, M. Ferreira, A. Aguilar, C. Jiménez, R. Selgas.

5:30pm-7:30pm: IL-17 Production Influenced by Induction Therapy With ATG

D. Abendroth,¹ M. Marzinzig,¹ J. Kaden.²

5:30pm-7:30pm: Ideal Versus Total Body Weight Dosing of Rabbit Anti-Thymocyte Globulin Induction Therapy on Patient Outcomes in High Immunological Risk Kidney Transplant

M. Vacha, J. Gommer, A. Rege, S. Sanoff, D. Sudan, M. Harris.

5:30pm-7:30pm: Immune-Mediated Injury in Kidney Transplant Recipients Treated With Alemtuzumab Induction and a Steroid Avoidance Protocol

R. Sapir-Pichhadze, T. Mahbub, C. Saw, D. Baran.

5:30pm-7:30pm: Induction With an Interleukin-2 Receptor Antagonist in Sensitized Adult Kidney Transplant Recipients Is Highly Effective and Safe

J. Casale, J. Fleming, D. Taber, C. Staino, K. Boyle, K. Covert, N. Pilch, H. Meadows, C. Mardis, K. Chavin, C. Bratton, J. McGillicuddy, P. Baliga.

5:30pm-7:30pm: Infections After Alemtuzumab Induction: A Non Issue?

A. Smith, M. John, I. Dortonne, A. Paramesh, M. Killackey, R. Zhang, B. Lee, J. Buell.

5:30pm-7:30pm: Kidney Patients at High Immunological Risk Can Be Safely Transplanted With a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab

D. Halleran,¹ J. Melancon,² V. Whittaker.¹

5:30pm-7:30pm: Long Term Outcomes With Alemtuzumab Induction Therapy for Deceased and Living Renal Transplant Recipients. A Single Center Experience

P. Vaitla, U. Patel, A. Cruz, S. Guisti, A. Moiz, C.-S. Catherine, A. Cohen, G. Loss, H. Bohorquez, I. Carmody, T. Reichman, D. Bruce, S. Anders, J. Garces.

5:30pm-7:30pm: Molecular Features of Kidney Transplant Biopsies Without Allograft Injury in Relation With Type of Induction Therapy

M. Ajaimy,¹ P. O Broin,² M. Lubetzky,¹ Y. Bao,¹ A. Golden,² E. Akalin.¹

5:30pm-7:30pm: Single Center Experience With the Use of an Abbreviated Anti-Thymocyte Globulin and Basiliximab Combination Protocol in Renal Transplantation

V. Whittaker,¹ D. Halleran,¹ S. Narsipar,¹ J. Melancon.²

5:30pm-7:30pm: The Relationship Between Age and Morbidity During the First Year Following Renal Transplantation in Patients Receiving Alemtuzumab Induction

S. LeCorchick, N. Wilson, C. Truscott, D. Shaffer, S. Karp, B. Concepcion, M. Stanley, I. Feurer, S. Bala.

5:30pm-7:30pm: Three Year Outcomes of Renal Allograft Transplants in African American Recipients Receiving Alemtuzumab for Induction Immunosuppression

P. Vaitla, H. Bohorquez, A. Cohen, A. Cruz, U. Patel, S. Anders, C.-S. Catherine, A. Moiz, S. Guisti, I. Carmody, G. Loss, D. Bruce, T. Reichman, J. Garces.

5:30pm-7:30pm: Thymoglobulin Dosing Efficacy: The Role of ALC on Infection and Rejection

H. Sarumi, C. Borscheid, G. Sieger, B. Fast, S. Hogan, K. Vassar, T. Pruett.

« View all sessions from the 2015 American Transplant Congress